Itraconazole in treatment of mCRPC: an update

Researchers at Johns Hopkins have, for a while, been investigating the potential of the antifungal agent itraconazole as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). We last reported on this research nearly a year ago, based on a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2011. … READ MORE …

Preliminary data on itraconazole in treatment of mCRPC

Preliminary data from a Phase II clinical trial have suggested that the antifungal drug itraconazole, when used at high dose levels, may have clinical benefit in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …